WHO Says No to TB Blood Tests

For the first time, WHO warns against the use of a diagnostic method.

By | July 19, 2011

Indian mother and child with TB.FLICKR, CALCUTTA RESCUE

The World Health Organization (WHO) will issue a recommendation against the use of widely available blood tests for the diagnosis of tuberculosis (TB) later this week. The warning—an unprecedented move for the organization—comes as a response to several studies that have found that the tests, which are commonly used in developing countries, produce too many false negatives and false positives to be considered reliable.

It is estimated that around one third of the world’s population is infected with Mycobacteria tuberculosis, but only around 5-10 percent of infected people develop the deadly respiratory disease. Currently, diagnostic methods in the United States and other developed countries consist of isolating and culturing the bacterium (known as the acid-fast smear test), as well as a nucleic acid amplification test for the bacterium’s DNA.

But in developing countries, there is a widespread and unregulated use of serodiagnostic kits, which detect antibodies against M. tuberculosis in the blood, often by organizations with financial motivation. “Many of these tests are used in the private-for-profit sector, charging poor people who do not understand the lack of value of the test,” Mario Raviglione, the director of WHO’s Stop TB department, told the Associated Press.

Add a Comment

Avatar of: You

You

Processing...
Processing...

Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo

Comments

Avatar of: Prasanta K Ghosh

Anonymous

July 20, 2011

Righr advice, but came quite late!

Avatar of:

Posts: 0

July 20, 2011

Righr advice, but came quite late!

Avatar of:

Posts: 0

July 20, 2011

Righr advice, but came quite late!

Popular Now

  1. How Plants Evolved Different Ways to Make Caffeine
  2. Thomson Reuters Predicts Nobelists
    The Nutshell Thomson Reuters Predicts Nobelists

    According to citation statistics, researchers behind programmed cell death pathways and CRISPR/Cas9 are among those in line for Nobel Prizes this year.

  3. Monsanto Buys Rights to CRISPR
    The Nutshell Monsanto Buys Rights to CRISPR

    The US agribusiness secures a global, nonexclusive licensing agreement from the Broad Institute to use the gene-editing technology for agricultural applications.

  4. Reviewing Results-Free Manuscripts
    The Nutshell Reviewing Results-Free Manuscripts

    An open-access journal is trialing a peer-review process in which reviewers do not have access to the results or discussion sections of submitted papers.

RayBiotech